WuXi AppTec's 2023 sales large­ly re­liant on the US, re­port says

WuXi AppTec’s an­nu­al re­port on Mon­day re­veals what’s at stake for the Shang­hai-based ser­vice provider if the BIOSE­CURE bill pass­es, which would re­strict the com­pa­ny from work­ing with US bio­phar­ma com­pa­nies.

As much as 65% of WuXi AppTec’s 2023 rev­enue came from US-based cus­tomers, with the man­u­fac­tur­er fore­cast­ing a sin­gle-dig­it rev­enue in­crease this year “de­spite un­cer­tain­ties in the ex­ter­nal en­vi­ron­ment,” as per the com­pa­ny’s an­nu­al re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER